Pharmacoeconomic Analysis of Fondaparinux Versus Enoxaparin for the Prevention of Thromboembolic Events in Orthopedic Surgery Patients

[1]  G. de Pouvourville,et al.  The cost‐effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery , 2003, Journal of thrombosis and haemostasis : JTH.

[2]  D. W. Hawkins,et al.  Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. , 2006, Cardiovascular drug reviews.

[3]  S. O’Brien,et al.  Managing cutaneous reactions to imatinib therapy. , 2002, Blood.

[4]  B. Eriksson,et al.  Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. , 2002, Archives of internal medicine.

[5]  B. Eriksson,et al.  Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism , 2002, Current opinion in pulmonary medicine.

[6]  Bengt I Eriksson,et al.  Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial , 2002, The Lancet.

[7]  P. Jacobs,et al.  An Economic Comparison of Enoxaparin and Warfarin in the Prevention of Deep Vein Thrombosis after Hip and Knee Replacement , 2002 .

[8]  B. Eriksson,et al.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. , 2001, The New England journal of medicine.

[9]  B. Eriksson,et al.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. , 2001, The New England journal of medicine.

[10]  G. Pineo.  New Developments in the Prevention and Treatment of Venous Thromboembolism , 2001, Pharmacotherapy.

[11]  M. Kovacs,et al.  Outpatient Treatment of Pulmonary Embolism with Dalteparin , 2000, Thrombosis and Haemostasis.

[12]  G. Raskob,et al.  The Economic Impact of Treating Deep Vein Thrombosis with Low-Molecular-Weight Heparin: Outcome of Therapy and Health Economy Aspects , 1998, Pathophysiology of Haemostasis and Thrombosis.

[13]  P. Wells,et al.  Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[14]  E W Salzman,et al.  Deep-vein thrombosis. , 1994, The New England journal of medicine.

[15]  G. Oster,et al.  A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. , 1987, JAMA.

[16]  F. Stadil.  Prevention of venous thrombosis. , 1970, Lancet.